Omass Omass
Life is interaction
Harnessing proprietary biochemistry, native mass spectrometry and custom chemistry to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell
OMass is an Oxford University spin-out backed by Syncona and Oxford Science Enterprises.

OMass Therapeutics


To meaningfully improve the lives of patients with orphan or immunological diseases.

OMass Therapeutics


To leverage our proprietary platform to discover medicines against highly validated but inadequately drugged targets.

Our Latest News
OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical...
OMass Announces Publication in Nature Methods
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in...
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
Oxford, 25 February 2020 - OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton - OMass Therapeutics...